Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Ingram Micro Inc. , a business-to-business (B2B) platform company for the global technology ecosystem, today announced its two partner communities?Ingram Micro SMB Alliance and Ingram Micro Trust X ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

In August 2024, the FDA granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Ocaliva (obeticholic acid) is a prescription drug that’s used to treat primary biliary cholangitis (PBC). Ocaliva comes as an oral tablet. Ocaliva is used to treat primary biliary cholangitis ...

Background: The purpose of the present study was to define the differential diagnostic markers of benign and malignant bile duct strictures without demonstrable mass on ultrasonography (US) or ...

The role of microbiological analysis of bile from patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) is unclear. Although the majority of such patients have positive ...

Which of the statements below about the guidelines of primary biliary cholangitis (PBC) are correct? Select one of the options for each question, then submit your answers to see how well you scored ...